Ocean Biomedical collaborates with leading researchers to develop preclinical drug candidates targeting oncology, fibrosis, and malaria, utilizing discoveries in chitinase biology and novel malaria antigens. The company aims to provide effective treatments for diseases that significantly impact global health, including severe malaria, which affects millions annually.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing effective treatments for diseases like cancer, fibrosis, and malaria remains a significant challenge, requiring innovative approaches to drug discovery and development. Traditional drug development pathways can be lengthy and costly, hindering the rapid translation of scientific breakthroughs into clinical solutions.
Solution
Ocean Biomedical partners with leading researchers and institutions to accelerate the development of novel preclinical drug candidates targeting oncology, fibrosis, and malaria. The company focuses on identifying and advancing promising discoveries in areas such as chitinase biology and novel malaria antigens. By providing capital and expertise, Ocean Biomedical aims to efficiently translate innovative ideas from the laboratory into transformative medicines that address unmet medical needs and improve global health outcomes. Their approach emphasizes collaboration and strategic partnerships to expedite the drug development process.
Target Audience
The primary target audience includes pharmaceutical companies, healthcare providers, and patients seeking innovative treatments for cancer, fibrosis, and malaria.
Features
- Focus on preclinical drug candidates targeting oncology, fibrosis, and malaria
- Collaboration with top-tier researchers and leading research institutions
- Utilization of discoveries in chitinase biology for therapeutic development
- Development of novel malaria antigens for potential malaria treatments
- Provision of capital and expertise to accelerate drug development